Disease Progression, Clinical Outcomes and Treatment Challenges in Patients with Chronic Kidney Disease and High-Risk Proteinuria
Advances in Therapy · 2025
DOI: 10.1007/s12325-025-03364-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Therapy, 2025. Verfasst von Roberto Pecoits-Filho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Arbor Research Collaborative for Health, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Proteinuria, Albuminuria, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Uppsala University.
Abstract (Originalsprache)
INTRODUCTION: A urine albumin-creatinine ratio (UACR) > 700 mg/g signifies severe kidney damage, and nephrology referral is recommended for intensified management. The impact of UACR ≥ 700 mg/g on outcomes and the efficacy of kidney protective therapies in patients have not been thoroughly examined. METHODS: Using claims healthcare data from the USA, we identified prevalent patients with chronic kidney disease and a UACR measurement on 1 January 2022, and grouped them by UACR level. We also identified new users of sodium-glucose cotransporter 2 inhibitors (SGLT2i) between 2021 and 2023. Outcomes included estimated glomerular filtration rate (eGFR) slopes and risks of adverse outcomes and mortality. RESULTS: Of the 46,626 patients with UACR ≥ 300 mg/g, 23,998 had UACR ≥ 700 mg/g. In the UACR ≥ 700 and UACR 300 to < 700 mg/g groups, mean age was 72 and 74 years, median eGFR was 42 and 50 mL/min/1.73 m2, median UACR was 1376 and 437 mg/g at baseline and eGFR slopes were - 5.5 and - 3.1 mL/min/1.73 m2 per year, respectively. Compared to the UACR < 10 mg/g group, adjusted hazard ratio of risk of cardiorenal hospitalizations was 5.83 (95% CI 5.55-6.12) and 3.53 (95% CI 3.34-3.73), atherosclerotic cardiovascular disease hospitalizations was 2.97 (95% CI 2.76-3.19) and 2.33 (95% CI 2.15-2.52), and all-cause death was 2.89 (95% CI 2.78-3.02) and 2.10 (95% CI 2.01-2.20) in the UACR ≥ 700 and UACR 300 to < 700 mg/g groups, respectively. Of the 5908 new users of SGLT2i with UACR ≥ 700 mg/g, UACR and eGFR slope improved as expected (to 720 mg/g and - 2.44 mL/min/1.73 m2 per year, respectively). CONCLUSIONS: A UACR ≥ 700 mg/g identifies patients at high risk of accelerated kidney function decline and adverse outcomes. While emerging therapies such as SGLT2i had the expected benefits, the persistence of residual proteinuria/albuminuria and associated risks highlight an unmet need for optimized and new treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Arbor Research Collaborative for Health, Ann Arbor, MI, USA.
- School of Medicine, Pontifical Catholic University of Paraná, Curitiba, Paraná, Brazil.
- RWE Research, Oslo, Norway.
- Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
- Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
- Statisticon AB, Uppsala, Sweden.
Förderung
- Uppsala University
Zitieren
APA
Pecoits-Filho, R., Bodegård, J., Ambery, P., Nam, Y. S., Thuresson, M., & Svensson, M. K. (2025). Disease Progression, Clinical Outcomes and Treatment Challenges in Patients with Chronic Kidney Disease and High-Risk Proteinuria. Advances in Therapy. https://doi.org/10.1007/s12325-025-03364-8
Vancouver
Pecoits-Filho R, Bodegård J, Ambery P, Nam YS, Thuresson M, Svensson MK. Disease Progression, Clinical Outcomes and Treatment Challenges in Patients with Chronic Kidney Disease and High-Risk Proteinuria. Advances in Therapy. 2025. doi:10.1007/s12325-025-03364-8
BibTeX
@article{PecoitsFilho2025,
author = {Pecoits-Filho, Roberto and Bodegård, Johan and Ambery, Phil and Nam, You-Seon and Thuresson, Marcus and Svensson, Maria K},
title = {Disease Progression, Clinical Outcomes and Treatment Challenges in Patients with Chronic Kidney Disease and High-Risk Proteinuria},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-025-03364-8}
}
EUVIMED